154 related articles for article (PubMed ID: 30396917)
21. Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.
Ferrari N; Granata I; Capaia M; Piccirillo M; Guarracino MR; Venè R; Brizzolara A; Petretto A; Inglese E; Morini M; Astigiano S; Amaro AA; Boccardo F; Balbi C; Barboro P
Cell Commun Signal; 2017 Dec; 15(1):51. PubMed ID: 29216878
[TBL] [Abstract][Full Text] [Related]
22. Simvastatin delays castration‑resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin‑1.
Gao Y; Li L; Li T; Ma L; Yuan M; Sun W; Cheng HL; Niu L; Du Z; Quan Z; Fan Y; Fan J; Luo C; Wu X
Int J Oncol; 2019 Jun; 54(6):2054-2068. PubMed ID: 31081050
[TBL] [Abstract][Full Text] [Related]
23. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer.
Han CS; Patel R; Kim IY
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):967-75. PubMed ID: 25936418
[TBL] [Abstract][Full Text] [Related]
25. Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.
Tilki D; Schaeffer EM; Evans CP
Eur Urol Focus; 2016 Dec; 2(5):499-505. PubMed ID: 28723515
[TBL] [Abstract][Full Text] [Related]
26. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
27. Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics.
Polotti CF; Kim CJ; Chuchvara N; Polotti AB; Singer EA; Elsamra S
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1265-1273. PubMed ID: 29137489
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of Therapeutic Resistance in Prostate Cancer.
Nakazawa M; Paller C; Kyprianou N
Curr Oncol Rep; 2017 Feb; 19(2):13. PubMed ID: 28229393
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials.
Wang Y; Zhang H; Shen W; He P; Zhou Z
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1751-1768. PubMed ID: 29797220
[TBL] [Abstract][Full Text] [Related]
30. Sequencing current therapies in the treatment of metastatic prostate cancer.
Valenca LB; Sweeney CJ; Pomerantz MM
Cancer Treat Rev; 2015 Apr; 41(4):332-40. PubMed ID: 25784591
[TBL] [Abstract][Full Text] [Related]
31. Androgen deprivation of prostate cancer: Leading to a therapeutic dead end.
Katzenwadel A; Wolf P
Cancer Lett; 2015 Oct; 367(1):12-7. PubMed ID: 26185001
[TBL] [Abstract][Full Text] [Related]
32. Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.
Beltran H; Antonarakis ES; Morris MJ; Attard G
Am Soc Clin Oncol Educ Book; 2016; 35():131-41. PubMed ID: 27249694
[TBL] [Abstract][Full Text] [Related]
33. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
[TBL] [Abstract][Full Text] [Related]
34. Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy.
Narayanan S; Srinivas S; Feldman D
Nat Rev Urol; 2016 Jan; 13(1):47-60. PubMed ID: 26643568
[TBL] [Abstract][Full Text] [Related]
35. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
Bastos DA; Dzik C; Rathkopf D; Scher HI
Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
[TBL] [Abstract][Full Text] [Related]
36. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
Sabnis NG; Miller A; Titus MA; Huss WJ
Mol Cancer Res; 2017 Feb; 15(2):128-140. PubMed ID: 27856956
[TBL] [Abstract][Full Text] [Related]
37. A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance.
Jeong JH; Park SJ; Dickinson SI; Luo JL
Mol Cell; 2017 Jan; 65(1):154-167. PubMed ID: 28041912
[TBL] [Abstract][Full Text] [Related]
38. Targeting molecular resistance in castration-resistant prostate cancer.
Chandrasekar T; Yang JC; Gao AC; Evans CP
BMC Med; 2015 Sep; 13():206. PubMed ID: 26329698
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia induced cancer stem cell enrichment promotes resistance to androgen deprivation therapy in prostate cancer.
O'Reilly D; Johnson P; Buchanan PJ
Steroids; 2019 Dec; 152():108497. PubMed ID: 31521707
[TBL] [Abstract][Full Text] [Related]
40. Preclinical and Coclinical Studies in Prostate Cancer.
Chen M; Pandolfi PP
Cold Spring Harb Perspect Med; 2018 Apr; 8(4):. PubMed ID: 29038335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
